Paving the Way for New Tumor Markers
Executive Summary
Tumor markers are difficult business in the US. But several recent initiatives should make it easier to commercialize them. The FDA in September agreed to reclassify assays used to monitor the recurrence of tumors or for treatment response, allowingthem to be submitted as 510(k)s.